Category: BioTech

FB Nasdaq FB Facebook
Analysis, BioTech, Commodities, Diversified Tech, Finance, Global Equity, Mergers & Acquisitions, Semiconductors, Services Sector, Software, software, Tech IPO

Avon Takes Steps to Enhance its Corporate Governance; Shares Far From a Beauty

Avon Products AVP announced on Friday that independent chairman Fred Hassan would be stepping down immediately in light of ” his other professional commitments” (which presently include working as a managing director and partner at private-equity firm Warburg Pincus, as well as a director at Time Warner TWX and chairman of Bausch and Lomb) . Former Campbell Soup CPB CEO Doug Conant (a director since … Continue reading Avon Takes Steps to Enhance its Corporate Governance; Shares Far From a Beauty

John MeadyLeave a comment
BioTech, Finance

Biotech Stock in Spotlight: As the World Awaits Ebola Treatment, Tekmira Pharma In Prime Focus

The outbreak of the deadly and highly infectious Ebola disease in Africa has already claimed multiple lives. According to media reports many health workers including doctors and nurses have also fallen a prey to the worst outbreak of the disease. According to the World Health Organization (WHO), the disease first surfaced in 1976. Among other places, it affected the Yambuku village situated close to the … Continue reading Biotech Stock in Spotlight: As the World Awaits Ebola Treatment, Tekmira Pharma In Prime Focus

Richard Atkins
Gilead Sciences GILD NASDAQ:GILD
Analysis, BioTech, Commodities, Diversified Tech, Finance, Global Equity, Mergers & Acquisitions, Semiconductors, Services Sector, Software, software, Tech IPO

Avnet Reports Soft Sales to Western Markets, Growth in Asia

We’re maintaining our fair value estimate and moat rating for Avnet AVT after it reported third-quarter results that indicate trepidation from enterprise businesses in Western markets, but continued growth in emerging markets. Avnet generated $6.3 billion of total sales, in line with seasonality and our own expectations. Pro-forma sales to higher-margin Western markets (EMEA and Americas) declined year-overyear in both of Avnet’s segments—electronics marketing (EM) … Continue reading Avnet Reports Soft Sales to Western Markets, Growth in Asia

John MeadyLeave a comment
BioTech, Finance

Active Biotech Stock: Amgen Posts Q2 Earnings, Dominates News

Amgen (AMGN) reported second quarter 2014 earnings of $2.37 per share, well above the Consensus Estimate of $1.99 and the year-ago earnings of $1.88. Total revenues increased 11% to $5,180 million in the second quarter of 2014, beating the Consensus Estimate of $4,875 million. Including one-time items, second quarter earnings increased 22% to $2.01 per share. Second quarter total product revenues increased 8% from the … Continue reading Active Biotech Stock: Amgen Posts Q2 Earnings, Dominates News

Richard Atkins
Analysis, BioTech, Commodities, Diversified Tech, Finance, Global Equity, Mergers & Acquisitions, Semiconductors, Services Sector, Software, software, Tech IPO

Ametek Delivers Earnings Growth in First Quarter

Ametek AME delivered first-quarter earnings of $0.51 per diluted share, an 11% increase versus the first quarter of 2012. While operating margin performance was ahead of pace to meet our full-year expectation, revenue growth, including acquisitions, of 7% was a bit weaker than we anticipated. Management increased the bottom end of its full-year EPS guidance from $2.07 to $2.08, resulting in a new midpoint of … Continue reading Ametek Delivers Earnings Growth in First Quarter

John MeadyLeave a comment
BioTech, Finance

Biotech Stock to Watch: Vertex Pharma. Posts Q2 Results

Vertex Pharmaceuticals Inc.’s (VRTX) second-quarter 2014 loss came in at 79 cents per share (including stock-based compensation expense), much wider than the loss of 21 cents reported in the year-ago quarter. Second quarter 2014 loss was also wider than the Consensus Estimate of a loss of 74 cents. Excluding the impact of stock-based compensation expense, second quarter 2014 loss was 61 cents per share as … Continue reading Biotech Stock to Watch: Vertex Pharma. Posts Q2 Results

Richard Atkins